KyungdongPharm Logo

KyungdongPharm

Develops and manufactures prescription drugs, OTC products, and pharmaceutical ingredients.

011040 | KO

Overview

Corporate Details

ISIN(s):
KR7011040003
LEI:
Country:
South Korea
Address:
경기도 화성시 양감면 제약단지로 224-3, 화성시

Description

KyungdongPharm is a pharmaceutical company engaged in the development, manufacturing, and distribution of medicines. Since its establishment in 1975, the company has focused on producing a broad portfolio of specialized therapeutic drugs and general pharmaceuticals. Its product lines encompass prescription medicines, with a focus on areas such as liver therapy, and over-the-counter products, including its prominent painkiller brand, 'Geunal-N'. The company also manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates. Utilizing advanced production facilities and proprietary technology, KyungdongPharm is dedicated to developing high-quality medicines supported by clinical research to contribute to public health.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-16 00:00
주요사항보고서(교환사채권발행결정)
Korean 128.3 KB
2025-12-16 00:00
주요사항보고서(자기주식처분결정)
Korean 118.9 KB
2025-09-10 00:00
자기주식처분결과보고서
Korean 16.9 KB
2025-09-01 00:00
주요사항보고서(자기주식처분결정)
Korean 29.7 KB
2025-08-27 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 30.0 KB
2025-08-27 00:00
주식등의대량보유상황보고서(일반)
Korean 250.7 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-12 00:00
주식등의대량보유상황보고서(일반)
Korean 265.3 KB
2025-07-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-05-14 00:00
분기보고서 (2025.03)
Korean 1.5 MB
2025-05-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.8 KB
2025-04-16 00:00
주식등의대량보유상황보고서(일반)
Korean 261.5 KB
2025-04-15 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.6 KB
2025-03-28 00:00
정기주주총회결과
Korean 22.4 KB
2025-03-20 00:00
감사보고서제출
Korean 25.7 KB

Automate Your Workflow. Get a real-time feed of all KyungdongPharm filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KyungdongPharm

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KyungdongPharm via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Biopharmaceutical firm developing cannabinoid-based medicines for inflammatory conditions.
United Kingdom
ANAN
Designs, develops, and manufactures molecular diagnostic solutions and instruments.
Türkiye
ANGEN
ANAVEX LIFE SCIENCES CORP. Logo
Clinical-stage biopharmaceutical company developing therapeutics for CNS disorders.
United States of America
AVXL
Anbio Biotechnology Logo
Develops and provides in-vitro diagnostic (IVD) solutions and instruments.
United States of America
NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing therapies for acute cannabinoid intoxication.
United States of America
ANEB
AnGes, Inc. Logo
Biopharmaceutical firm developing gene-based and nucleotide-based medicines.
Japan
4563
Anika Therapeutics, Inc. Logo
A global joint preservation company developing solutions for orthopedic care.
United States of America
ANIK
ANIMALCARE GROUP PLC Logo
Develops and commercializes veterinary pharmaceutical products and services globally.
United Kingdom
ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded, generic, and OTC pharmaceutical products.
United States of America
ANIP
Annexin Pharmaceuticals AB Logo
Clinical-stage biotech developing a cell-protecting biologic for RVO and oncology.
Sweden
ANNX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.